Radiation-Induced Myelosuppression Treatment Market

Radiation-Induced Myelosuppression Treatment Market: Accelerated Approvals from Regulatory Authorities for Novel Biosimilar Drugs Anticipated to Boost Growth: Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028

  • 2019-01-17
  • REP-GB-8116
  • 207 pages
  • PDF PPT EXCEL
 Radiation-Induced Myelosuppression Treatment Market
  • SELECT LICENSE :

  • US$5,000
  • US$7,500
  • US$10,000

Radiation-Induced Myelosuppression Treatment – Increasing Incidence of Cancer

Growing incidence of cancer worldwide and decreased death rate owing to early diagnosis and the availability of innovative treatment options such as radiotherapy and chemotherapy are among factors expected to fuel the growth of the radiation-induced myelosuppression treatment market. In addition, the increasing adoption of adjuvant therapy for cancer, i.e., chemotherapy along with radiotherapy, has a significant impact on the declining death rate as well as the management of cancer, along with the quality of life in patients suffering from cancer.

Radiation-Induced Myelosuppression Treatment Market - Key Research Findings

  1. Global radiation-induced myelosuppression treatment market size in 2018 – nearly US$ 2,500 Mn.

  2. The radiation-induced myelosuppression treatment market is expected to grow at an approximate CAGR of 3.4% over 2018-2028.

  3. North America is expected to remain a prominent regional market for radiation-induced myelosuppression treatment

    • North America’s position in the radiation-induced myelosuppression treatment market can be attributed to an increase in the number of patients suffering from myelosuppression
  4. New drug approvals and launches are expected to help companies exploit the growth prospects of the radiation-induced myelosuppression treatment market

    • Manufacturers in the radiation-induced myelosuppression treatment market are focusing on getting approvals and launching various biologics as well as small molecules. The recent patent expiry of various biologics has offered the opportunity for manufacturers to launch new biosimilars.
    • For example, in May 2018, FDA approved Pfizer’s first erythropoiesis-stimulating agent (ESA) biosimilars for biologics launch by Amgen Inc. (Epogen) and Procrit launched by Janssen Pharmaceutical NV
    • In June 2018, FDA approved the first biosimilar Fulphila manufactured by Mylan N.V. to Amgen Inc.’s Neulasta (Pegfilgrastim) biologics.

Top 2 Factors Shaping the Global Radiation Induced Myelosuppression Treatment Market

The Availability of Drugs for the Treatment of Anemia and Thrombocytopenia

The management of neutropenia has become easier with the availability of various growth factors as well as that of desired treatment guidelines for their management. However, anemia and thrombocytopenia remain among the major clinical problems. Although thrombocytopenia is effectively managed with the help of the available growth factors, most of them are off-label. The management of anemia remains one of the high unmet needs among cancer patients who receive radiation therapy for cancer treatment. Due to changes in the reimbursement and labelling of anemia-associated drugs in 2007, the off-label indication use of erythropoietin-stimulating agents has decreased drastically owing to a reduction in their usage in anemia management. The above changes have increased the need for blood transfusion, which is associated with various risk factors. Hence, the prevalence of radiotherapy-induced anemia offers a vast opportunity for revenue generation.

Increasing Use of ESA Along with Iron Supplements

Various studies pertaining to the off-label use of Erythropoiesis-Stimulating Agents (ESA) for the treatment of radiation induced anemia are being carried out. Moreover, due to a decrease in the use of ESA, various studies are focused on evaluating the response of ESA to anemia. The response rate of ESA alone in patients suffering from radiation-induced anemia is reported in between 62 and 73%, whereas the response of ESA when used along with iron supplements such as Feritin increased up to 72% – 86% (Auerbach et al.). By using ESA and iron therapy together, the need for blood transfusion in case of radiation-induced anemia has decreased substantially.

Radiation-Induced Myelosuppression Treatment Market Structure Analysis

  • The global radiation induced myelosuppression treatment market represents a consolidated competition landscape, wherein the major companies hold three-fourth of the revenue share
  • Most of the manufacturers in the radiation-induced myelosuppression treatment market are focusing on the North America and Europe regions
  • Manufacturers are focusing on strategic expansion through acquisitions & mergers with other companies around the world, and ensuring the availability of their products by strengthening their manufacturing facilities
  • The company also focuses on building a value chain to develop new products and sustainable solutions, as well as to optimize the generics portfolio to match demands with greater focus on profitability
  • Some of the prominent companies in the radiation-induced myelosuppression treatment market include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Amgen Inc., Janssen Global Services, LLC (Johnson & Johnson), Partner Therapeutics, Inc., Mission Pharmacal Company, Myelo Therapeutics GmbH, and Pluristem Therapeutics Inc.

Market is set to Grow Over 1.4X between 2018 and 2028

The radiation-induced myelosuppression treatment market is likely to witness moderate growth over the forecast period, which is expected to be driven by the increasing usage of radiotherapy for cancer treatment, as well as the increasing usage of ESA along with iron supplements. Furthermore, the use of radiation in cancer treatment is increasing due to its site-specific nature, which is among the most important factors for the early diagnosis of cancer patients. This is another factor that is expected to propel the radiation-induced myelosuppression treatment market.

Stakeholders Aiming at Tapping the Potential of Emerging Markets

There are several opportunities for the growth of the radiation-induced myelosuppression treatment market across emerging economies such as China, India, and GCC countries. The company operating in the market are continuously making efforts to sustain future growth through the expansion of indications for their already approved drugs. Companies are expanding their presence in developing regions such as Latin America and Asia Pacific.

* This data is only a representation. Actual data may vary and will be available in report.

Stakeholders Aiming at Tapping the Potential of Emerging Markets
Stakeholders Aiming at Tapping the Potential of Emerging Markets
Stakeholders Aiming at Tapping the Potential of Emerging Markets
Stakeholders Aiming at Tapping the Potential of Emerging Markets
  • 2014
  • 2018
  • 2022
  • 2028
  • Arrow

The Broader Perspective

The radiation-induced myelosuppression treatment market continues to witness growth as companies focus on the launch and approval of biosimilars due to the patent expiry of various drugs. Increase in research and development to increase the ease of managing cancer therapy-associated adverse effects is expected to further fuel the radiation-induced myelosuppression treatment market.

Growth Factors remain among the core drug types due to their comparatively higher efficacy and abundant availability across the world. The growth of this drug type can be mainly attributed to the increasing benefits offered by these drugs, low adverse effects, and the higher adoption of growth factors such as G-CSF and thrombopoietin receptor agonists.

Thrombopoietic Agents Drugs are likely to grow at a sluggish rate

Iron Supplementation Drugs are likely to witness moderate growth

The oral route of administration segment is likely to growth at a significant rate during the forecast period

The injectable route of administration segment accounts for more than three fourth share of the total market share due to high adoption

Neutropenia - The most lucrative indication in the radiation-induced myelosuppression treatment industry, which is expected to create an opportunity of over US$ 1,300 Mn by 2029

Anaemia - Likely to grow at a moderate rate

Retail Pharmacies remain among the prominent distribution channels, with nearly 45% revenue share

Demand from Online Pharmacies to grow at a rapid rate

How Growth will Unfold

ESA are expected to account for the second most lucrative segment in the radiation-induced myelosuppression treatment market by drug type owing to the improved efficacy of iron therapy with ESA. IV iron therapy, along with ESA, helps bring back the RBC count to normal as compared to the treatment of ESA alone. This significant change in the response rate is expected to help improve the efficacy and therapeutic outcome, as well as patient compliance. These factors are estimated to boost the demand for ESA in the radiation-induced myelosuppression treatment market.

Growth Factors | ESA | Thrombopoietic Agents | Iron supplementation | Others

 Radiation-Induced Myelosuppression Treatment Market  Radiation-Induced Myelosuppression Treatment Market  Radiation-Induced Myelosuppression Treatment Market

* This data is only a representation. Actual data may vary and will be available in report.

Click Here To Know How The Growth Will Unfold

Custom Market Research Services

FMI offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Overview

Radiation-Induced Myelosuppression Treatment Market: Global Industry Analysis 2013–2017 & Opportunity Assessment, 2018–2028

A recent market study published by the company “Radiation-Induced Myelosuppression Treatment Market: Global Industry Analysis 20132017 & Opportunity Assessment, 2018–2028” consists of a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historic as well as current growth parameters of the radiation-induced myelosuppression treatment market, the growth prospects of the market are obtained with maximum precision. The report features the unique and salient factors that are likely to significantly impact the development of the radiation-induced myelosuppression treatment market during the forecast period. It can help market players modify their manufacturing and marketing strategies to envisage maximum growth in the radiation-induced myelosuppression treatment market in the upcoming years. The report provides detailed information about the current and future growth prospects of the radiation-induced myelosuppression treatment market in the most comprehensive manner for the better understanding of readers.

Radiation Induced Myelosuppression Treatment Market Taxonomy

The global radiation-induced myelosuppression treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach in front of the reader.

By Product

  • Growth Factors
    • Granulocyte Colony Stimulating Factors
    • Thrombopoietin Receptor Agonists
  • Erythropoietin Stimulating Agents
  • Thrombopoietic Agents
  • Iron Supplement
  • Others

By Indication

  • Neutropenia
  • Anemia
  • Thrombocytopenia

By Distribution Channel

  • Oral
  • Injectable

By Route of Administration

  • Oral
  • Injectable

Region

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

What's Included

The report commences with the executive summary of the radiation-induced myelosuppression treatment market, which includes the summary of key findings and key statistics of the market. It also includes the market value (US$ million) estimates of the leading segments of the radiation-induced myelosuppression treatment market.

Readers can find detailed taxonomy and the definition of the radiation-induced myelosuppression treatment market in this chapter, which will help them understand the basic information about the radiation-induced myelosuppression treatment market dynamics, supply chain, cost structure and pricing analysis. A list of key distributors and suppliers, as well as a list of key market participants is included in the report.

This chapter includes a detailed analysis of the growth of the North America radiation-induced myelosuppression treatment market along with a country-wise assessment that includes the U.S. and Canada. Readers can also find regional trends, regulations and market growth based on the end users and countries in North America.

Readers can find detailed information about several factors, such as the pricing analysis and the regional trends, which are impacting the growth of the Latin America radiation-induced myelosuppression treatment market. This chapter also includes the growth prospects of the radiation-induced myelosuppression treatment market in the leading LATAM countries such as Brazil, Mexico, Argentina and Rest of Latin America.

Important growth prospects of the radiation-induced myelosuppression treatment market based on its end users in several countries, such as Germany, the UK, France, Spain, Italy and Rest of Western Europe, are included in this chapter.

Important growth prospects of the radiation-induced myelosuppression treatment market based on its product types and applications in several countries, such as Russia, Poland and the Rest of Eastern Europe, are included in this chapter.

China, India, ASEAN, Australia and New Zealand are the leading countries in the APEJ region, which are the prime subjects of assessment to obtain the growth prospects of the APEJ radiation-induced myelosuppression treatment market in this chapter. Readers can find detailed information about the growth parameters of the APEJ radiation-induced myelosuppression treatment market during the period 2018–2028.

Readers can find important factors that can significantly impact the growth of the radiation-induced myelosuppression treatment market in Japan during the forecast period based on the market segmentation.

This chapter provides information about how the radiation-induced myelosuppression treatment market will grow in the major countries in the MEA region, such as GCC Countries, South Africa and the rest of MEA, during the period 2018–2028.

In this chapter, readers can find a comprehensive list of all the leading stakeholders in the radiation-induced myelosuppression treatment market along with detailed information about each company, which includes the company overview, revenue shares, strategic overview and recent company developments. Some of the market players featured in the report are Amgen Inc., Janssen Pharmaceutical NV, Teva Pharmaceutical Industries Ltd., Mylan NV, Novartis AG, Pfizer Inc., Janssen Global Services, LLC (Johnson & Johnson) and Partner Therapeutics, Inc.

Based on the type, the radiation-induced myelosuppression treatment market is segmented into growth factors, erythropoietin stimulating agents, thrombopoietic agents, iron supplements and others. In this chapter, readers can find information about the key trends and developments in the radiation-induced myelosuppression treatment market and market attractiveness analysis based on the type.

Based on the indication, the radiation-induced myelosuppression treatment market is segmented into neutropenia, anaemia and thrombocytopenia. In this chapter, readers can find information about the key trends and developments in the radiation-induced myelosuppression treatment market and market attractive analysis based on indication.

Based on the Route of Administration, the radiation-induced myelosuppression treatment market is segmented into oral and injectable. In this chapter, readers can find information about the key trends and developments in the radiation-induced myelosuppression treatment market and market attractive analysis.

Based on the distribution channel, the radiation-induced myelosuppression treatment market is segmented into hospital pharmacies, retail pharmacies, drug stores and online pharmacies. In this chapter, readers can find information about the key trends and developments in the radiation-induced myelosuppression treatment market and market attractive analysis based on the distribution channel for each region.

This chapter explains how the radiation-induced myelosuppression treatment market will grow across various geographic regions, such as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan, Japan and Middle East & Africa (MEA).

This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the radiation-induced myelosuppression treatment report.

This chapter helps readers understand the research methodology followed to obtain the various conclusions as well as important qualitative and quantitative information about the radiation-induced myelosuppression treatment market.

How the research was conducted?

Primary Research

  • C - Level Executives
  • Marketing Directors
  • Sales Heads
  • Portfolio Managers
  • Purchasing Managers
  • Medical Officers
  • Drug Development Heads
  • Strategy Advisors
  • R&D Managers
  • Product Manufacturers
  • Distributors
  • Pharmacists / Pharmacy Benefit Managers
  • Hospital Purchasing Departments
  • Physicians / Nursing Managers
  • Industry Experts
  • Current Market Dynamics and Challenges
  • Market Characteristics
  • Market Performance and Growth Quadrants
  • Competition Structure and Market Structure
  • Strategic Growth Initiatives
  • Disease Patterns, Treatment and Prescription Patterns
  • Regulatory and Reimbursement Landscape
  • Products in Pipeline and Clinical Development
  • Near-term and Long-term Market Growth Prospects
  • Market Segment Splits and Authenticity
  • Opinions on Market Projections and Validity of Assumptions

Secondary Research

  • Industry Magazines
  • Industry Associations
  • Factiva
  • Company Press Releases
  • Annual Reports and Investor Presentations
  • Peer-reviewed Journals
  • Government Websites and Publications
  • Trade Websites
  • Clinical Trial Registries
  • Country-specific Regulatory Authorities
  • World Bank, WHO, IMF, OECD

Primary Interview Splits

Primary Research Interview Splits

Radiation Induced Myelosuppression Treatment Market Reports - Table of Contents

To Learn More About our Comprehensive Perspective on Radiation-Induced Myelosuppression Treatment Market,

Get in touch

Harish Tiwari

Harish Tiwari

Global Head - Business Development

Pranay Mhaisekar

Pranay Mhaisekar

Client Partner - Global Business Development

* indicates mandatory fields

Our Clients


CASE STUDIES

See how our work makes an impact.

At FMI, we design strategies that are adaptive, impactful, and implementable.

Request Sample Ask An Analyst Request Methodology